exatecan

Exatecan (DX-8951f) is a DNA topoisomerase I (TOP1) inhibitor with an IC50 value of 2.2 μM (0.975 μg/mL).Exatecan has antitumor activity and may be used in cancer research.

Exatecan Mesylate (DX8951f) is a DNA topoisomerase I inhibitor (IC50: 2.2 μM, 0.975 μg/mL).

(4-NH2)-Exatecan is a topoisomerase inhibitor with potential anticancer activity for the synthesis of antibody drug conjugates (ADCs).

Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan is a linker molecule employed in the synthesis of antibody-drug conjugates (ADCs), demonstrating potent antitumor activity both in vitro and in vivo [1].

Gly-Mal-Gly-Gly-Phe-Gly-amide-methylcyclopropane-Exatecan is a compound utilized in the synthesis of Antibody-Drug Conjugates (ADCs) [1].

MC-Val-Cit-PAB-Exatecan (MC-Val-Cit-PAB-DX8951) is a conjugate of the DNA topoisomerase I inhibitor DX-8951 and a cathepsin-cleavable antibody-drug conjugate (ADC) linker, designed for targeted cancer therapy applications.

(αR)-Cyclopropaneacetamide-Exatecan (compound 2-A), an Exenotecan derivative, serves as a cytotoxic agent that effectively inhibits the proliferation of U87MG and SK-BR-3 cells, exhibiting IC50 values of 8.11 and 2.31 μM, respectively [1].

(1-OH)-Exatecan, a quinoline ring compound, exhibits substantial antiproliferative effects and is utilized in research for cancer diseases [1].

MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan is an agent-linker conjugate for antibody-drug conjugates (ADCs), incorporating Exatecan, a DNA Topoisomerase I inhibitor (IC 50 = 2.2 μM) [1].

Compound 15, Mal-PEG8-Phe-Lys-PAB-Exatecan, is an antibody-drug conjugate (ADC) comprised of the degradable linker Mal-PEG8-Phe-Lys-PAB and the cytotoxic agent Exatecan [1].

Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan is a conjugated compound utilized in the synthesis of antibody-drug conjugates (ADCs). This chemical includes a topoisomerase inhibitor derivative attached via a linker, facilitating the connection to a specific ligand unit[1].

Val-Ala-PABC-Exatecan trifluoroacetate is a drug-linker conjugate for antibody-drug conjugates (ADC), comprising a cleavable Tesirine linker, Val-Ala-PABC, and the topoisomerase I inhibitor Exatecan. This compound facilitates the synthesis of ADC molecules, including Mal-PEGn-amide-va-Exatecan [1].

Exatecan mesylate dihydrate (DX-8951), a DNA topoisomerase I inhibitor, exhibits an IC50 of 2.2 μM (0.975 μg/mL) and is utilized in cancer research [1] [2] [3].

Exatecan-amide-cyclopropanol is an anticancer agent that inhibits the proliferation of SK-BR-3 cells (IC50: 0.12 nM) and U87 cells (IC50: 0.23 nM).

MC-Gly-Gly-Phe-Gly-(S)-Cyclopropane-Exatecan is a agent-linker conjugates for ADC , consisting Exatecan . Exatecan is a DNA Topoisomerase I inhibitor (IC 50 =2.2 μM) [1] .

MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan is an agent-linker conjugate designed for antibody-drug conjugate (ADC) applications, comprising an ADC linker (MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic acid) and the DNA topoisomerase I inhibitor, Exatecan. This conjugate is utilized in cancer research [1].

Val-Ala-PABC-Exatecan is a Drug-Linker Conjugate for Antibody-Drug Conjugate (ADC) synthesis, comprising a cleavable Tesirine linker (Val-Ala-PABC) and the topoisomerase I inhibitor Exatecan. It is utilized in the construction of ADC molecules, including Mal-PEGn-amide-va-Exatecan [1].

Ac-Exatecan, the acetylated form of Exatecan (DX-8951), serves as a prevalent cytotoxic agent in antibody-drug conjugate (ADC) formulations (ADC Cytotoxin) and acts as an inhibitor of DNA topoisomerase I with an IC50 value of 2.2 μM [1].

Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan is a drug-linker conjugate for antibody-drug conjugates (ADCs), comprising Exatecan tethered by a maleimidopropyl (Mal) PEGylated tetrapeptide linker. It is utilized for the synthesis of ADCs and cancer research [1].

Gly-Cyclopropane-Exatecan, a DNA Topoisomerase I inhibitor containing Exatecan, is key in synthesizing the anti-B7-H4 ADC, specifically the ADC hu2F7-Exatecan (compound 34). This compound demonstrated antitumor activity both in vivo and in vitro [1].

Exatecan Intermediate 1 is a useful organic compound for research related to life sciences. The catalog number is T67020 and the CAS number is 110351-94-5.

Mal-PEG8-Phe-Lys-PAB-Exatecan TFA is a conjugate for ADC comprised of the degradable linker Mal-PEG8-Phe-Lys-PAB and the cytotoxic agent Exatecan [1].

MC-Gly-Gly-Phe-Gly-amide-cyclopropanol-amide-Exatecan is an antibody-drug conjugate (ADC)[1].

Exatecan TFA, a methylpropanamide-modified derivative of the common ADC cytotoxin Exatecan, serves as a DNA topoisomerase I inhibitor with an IC50 of 2.2 μM (0.975 μg/mL), utilized in the synthesis of ADCs for cancer research [1].

MC-VA-PAB-Exatecan is an agent-linker conjugate designed for Antibody-Drug Conjugate (ADC) applications, comprising the ADC linker (peptide MC-VA-PAB) and the DNA topoisomerase I inhibitor Exatecan. Synthesis of this conjugate has demonstrated promising antitumor activity [1].

Mal-PEG8-Val-Ala-PAB-Exatecan (Compound 9b), an antibody-drug conjugate linker (ADC linker), binds Nectin-4 polypeptides to chemotherapeutic agents for use in cancer research [1].

Exatecan (Intermediate 2), a derivative of GGFG-amide-glycol-amide-Exatecan, facilitates the synthesis of antibody-drug conjugates (ADCs) [1].

Mal-Gly-PAB-Exatecan-D-glucuronic acid is utilized in the synthesis of Antibody-Drug Conjugates (ADCs) and is also valuable in the research and diagnosis of tumors [1].

Cyclooctyne-O-amido-PEG4-VC-PAB-Gly-Gly-NH-O-CO-Exatecan is a drug-linker conjugate utilized in Antibody-Drug Conjugates (ADC Cytotoxin: Exatecan) [1].

Dxd (OQM5SD32BQ) is a potent inhibitor of DNA topoisomerase I with an IC50 of 0.31 μM. It is used as a conjugated drug of HER2-targeting ADC.

PB038 is a drug-like molecule that incorporates a PEG (polyethylene glycol) unit and a cleavable linker conjugated to Exatecan [1].

Eribulin-GGFG (Compound GGFG) is a drug-linker conjugate for antibody-drug conjugates (ADCs). Comprised of the cytotoxic agent exatecan and a connecting linker, it facilitates the synthesis of ADCs [1].

PB089 is a drug-like molecule featuring a polyethylene glycol (PEG) unit and a cleavable linker connected to Exatecan [1].